Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 3Endometrial Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Melanoma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Bites and Stings 1Adenocarcinoma 1

Interventions

pembrolizumab 6Nivolumab 5cemiplimab 3Photochemotherapy 3Ipilimumab 3Vemurafenib 2Hsp90 inhibitor KU757 2tozuleristide 1toripalimab 1tislelizumab 1spartalizumab 1small molecule inhibitor THX-B 1poly ICLC 1montanide ISA 51 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cobimetinib 1cc-486 1brodalumab 1avelumab 1atezolizumab 1Ultraviolet Rays 1Tumor Necrosis Factor-alpha 1Sunscreening Agents 1Sugars 1SUB1 protein, human 1Radiotherapy 1Propranolol 1Poly I-C 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Skin Neoplasms × dostarlimab × Clear all
NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

University of Southern California

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡